Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of cluster-regimen ALUSTAL subcutaneous allergen immunotherapy in allergic rhinitis/rhinoconjunctivitis and mild-to-moderate allergic asthma
2005-003008-12Phase 4Active
- Sponsor
- Stallergenes Greer
- Start
- Sep 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Olea europaea allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma (3 arms), sponsored by Stallergenes Greer. Primary endpoint: Primary safety endpoint. Started Sep 2005; status: active.
02
Drugs
Olea europaea allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2005-003008-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003008-12.